SCHEMBL5520692

SCHEMBL5520692

CCN(CC)CCOc1ccc(Nc2ncc3nc(-c4c(Cl)c(OC)nc(OC)c4Cl)c(=O)n(C)c3n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 10/20 0.62
NOD2 Q9HC29 10/20 0.62
ACVR1 Q04771 7/20 0.61
WEE1 P30291 7/20 0.60
SRC P12931 3/20 0.60
FGFR1 P11362 2/20 0.60
CHEK1 O14757 1/20 0.60
JAK2 O60674 1/20 0.60
PRKD3 O94806 1/20 0.60
MAP4K4 O95819 1/20 0.60
PAK4 O96013 1/20 0.60
ABL1 P00519 1/20 0.60
EGFR P00533 1/20 0.60
NTRK1 P04629 1/20 0.60
LCK P06239 1/20 0.60
FYN P06241 1/20 0.60
CSF1R P07333 1/20 0.60
RET P07949 1/20 0.60
IGF1R P08069 1/20 0.60
MET P08581 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14595013 0.94 RIPK2 (0.57) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL5518142 0.87 RIPK2 (0.75) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL5514068 0.87 RIPK2 (0.65) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL5520426 0.83 RIPK2 (0.73) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL5516251 0.83 FGFR1 (0.58) RIPK2NOD2WEE1SRCFGFR1
SCHEMBL14594125 0.83 RIPK2 (0.68) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL14594178 0.83 RIPK2 (0.59) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL5523958 0.78 FGFR1 (0.58) WEE1SRCFGFR1LCKCSF1R
SCHEMBL14594126 0.77 FGFR1 (0.54) RIPK2NOD2ACVR1WEE1SRC
SCHEMBL4675870 0.77 FGFR1 (0.61) RIPK2NOD2ACVR1WEE1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US claimed
EP-1409487-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-04-21 EP claimed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US claimed
WO-2001019825-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-03-22 WO claimed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
EP-1409487-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-04-21 EP disclosed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US disclosed
WO-2001019825-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130286-A1 Pteridinones as kinase inhibitors CCNI, CCNK, CDK2 RIPK2 431/4885NOD2 3635/4885ACVR1 300/4885
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS CCNI, CCNK, CDK2 RIPK2 456/4885NOD2 3496/4885ACVR1 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.